ATAI ATAI LIFE SCIENCES BV

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company’s participation:

Format: Fireside chat and 1x1 investor meetings

Date and Time: Fireside chat on Wednesday August 14 at 11:00 A.M. EDT

Webcast link:

An archived replay will be available on the Investors section of the atai website under  for up to 90 days.

About atai Life Sciences

atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients. atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit .

Contact Information

Investor Contact:

Media Contact:



EN
07/08/2024

Underlying

ATAIATAI LIFE SCIENCES BV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ATAI LIFE SCIENCES BV

 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual G...

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company’s participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside...

September 4, 2024 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences Reports Second Quarter 2024 Financial Results and P...

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates • Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE’24  • Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disorder patients around YE’24  • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai...

August 13, 2024 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences Announces Positive Preliminary Results from Phase 1...

atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT) VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in interventional psychiatryVLS-01 reached peak plasma concentration within 30-45 minutes and was shown to induce a short psychedelic experience, with subjective effects generally resolving within 90-120 minutesVLS-01 demonstrated a favorable safety profile and was well tolerated, with all adverse events classified as either...

August 13, 2024 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual...

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company’s participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on W...

August 7, 2024 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Ne...

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company’s participation: Format: Virtual fireside chat and 1x1 investor meetingsDate and Time: Fireside chat available ...

June 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch